Vitamin B12 measurements across neurodegenerative disorders

Table 3 Multivariable analysis of factors associated with B12 level at time of diagnosis

Diagnosis	Coefficient^*	(95% CI)	P-value
Parkinson’s disease (PD)	Ref
Alzheimer’s disease (AD)	1.90	(−36.4, 40.2)	0.92
Dementia with Lewy bodies (DLB)	64.3	(1.94, 127)	0.04
Frontotemporal dementia (FTD)	76.4	(3.24, 149)	0.04
Mild cognitive impairment (MCI)	32.8	(−2.39, 68.0)	0.068
Multiple systems atrophy (MSA)	100.4	(−12.8, 214)	82
Progressive supranuclear palsy (PSP)	81.6	(2.55, 161)	0.04
Female gender	−7.65	(−32.6, 17.3)	0.55
Age at diagnosis	−0.86	(−2.14, 0.41)	0.185
Multivitamin use	93.5	(65.0, 122)	< 0.001
B12 supplementation	86.4	(34.3, 139)	0.001

*In a linear regression, coefficients are interpreted as follows: a one unit increase in x results in an increase in B12 pg/ml of (coefficient) pgs. For example, the coefficient associated with DLB is interpreted: Compared to patients with PD, patients with DLB have on average a B12 level that is 64.3 pg/ml higher at the time of diagnosis

ISSN: 2054-7072